Risk of Death in Comorbidity Subgroups of Hospitalized COVID-19 Patients Inferred by Routine Laboratory Markers of Systemic Inflammation on Admission: A Retrospective Study.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
31 05 2022
Historique:
received: 09 05 2022
revised: 27 05 2022
accepted: 28 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Our study objective was to construct models using 20 routine laboratory parameters on admission to predict disease severity and mortality risk in a group of 254 hospitalized COVID-19 patients. Considering the influence of confounding factors in this single-center study, we also retrospectively assessed the correlations between the risk of death and the routine laboratory parameters within individual comorbidity subgroups. In multivariate regression models and by ROC curve analysis, a model of three routine laboratory parameters (AUC 0.85; 95% CI: 0.79-0.91) and a model of six laboratory factors (AUC 0.86; 95% CI: 0.81-0.91) were able to predict severity and mortality of COVID-19, respectively, compared with any other individual parameter. Hierarchical cluster analysis showed that inflammatory laboratory markers grouped together in three distinct clusters including positive correlations: WBC with NEU, NEU with neutrophil-to-lymphocyte ratio (NLR), NEU with systemic immune-inflammation index (SII), NLR with SII and platelet-to-lymphocyte ratio (PLR) with SII. When analyzing the routine laboratory parameters in the subgroups of comorbidities, the risk of death was associated with a common set of laboratory markers of systemic inflammation. Our results have shown that a panel of several routine laboratory parameters recorded on admission could be helpful for early evaluation of the risk of disease severity and mortality in COVID-19 patients. Inflammatory markers for mortality risk were similar in the subgroups of comorbidities, suggesting the limited effect of confounding factors in predicting COVID-19 mortality at admission.

Identifiants

pubmed: 35746672
pii: v14061201
doi: 10.3390/v14061201
pmc: PMC9228480
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Front Immunol. 2020 Aug 11;11:1991
pubmed: 32903476
J Clin Lab Anal. 2020 Oct;34(10):e23566
pubmed: 32914892
Int J Med Inform. 2021 Nov;155:104594
pubmed: 34601240
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Allergy. 2021 Feb;76(2):533-550
pubmed: 32662525
PLoS One. 2022 Feb 3;17(2):e0263471
pubmed: 35113971
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Front Public Health. 2021 Jul 07;9:591982
pubmed: 34307267
Sci Rep. 2021 May 24;11(1):10738
pubmed: 34031483
Front Immunol. 2021 Sep 08;12:689966
pubmed: 34566957
PLoS One. 2021 Apr 1;16(4):e0249301
pubmed: 33793598
J Hepatol. 2020 Oct;73(4):995-996
pubmed: 32502510
Nat Commun. 2020 Sep 7;11(1):4439
pubmed: 32895375
Clin Immunol. 2021 Feb;223:108652
pubmed: 33333256
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Clin Chem Lab Med. 2020 Jul 28;58(8):1365-1371
pubmed: 32441666
Front Oncol. 2018 Mar 21;8:78
pubmed: 29619344
Am J Emerg Med. 2020 Nov;38(11):2444-2454
pubmed: 33039218
Nurs Open. 2021 May;8(3):1077-1088
pubmed: 34482663
PLoS One. 2021 Jul 6;16(7):e0253660
pubmed: 34228746
Front Immunol. 2021 Feb 18;12:631226
pubmed: 33679778
J Clin Lab Anal. 2021 Jan;35(1):e23657
pubmed: 33225517
BMC Infect Dis. 2007 Mar 02;7:10
pubmed: 17335562
PLoS One. 2013;8(2):e57121
pubmed: 23468921
Am J Emerg Med. 2021 Feb;40:110-114
pubmed: 33309506
Can Respir J. 2022 Mar 28;2022:5129314
pubmed: 35356088
PLoS One. 2021 Mar 31;16(3):e0248956
pubmed: 33788884
Mod Pathol. 2021 Mar;34(3):522-531
pubmed: 33067522
Int J Med Sci. 2021 Jan 14;18(5):1207-1215
pubmed: 33526982
Int Immunopharmacol. 2020 Nov;88:106950
pubmed: 32919217
PLoS One. 2021 Jun 29;16(6):e0253894
pubmed: 34185801
Front Med (Lausanne). 2022 Jan 04;8:671667
pubmed: 35059407
Front Immunol. 2021 Oct 21;12:769059
pubmed: 34745145
PLoS One. 2020 Aug 21;15(8):e0238160
pubmed: 32822430
J Clin Med Res. 2020 Jul;12(7):448-453
pubmed: 32655740
Eur J Clin Invest. 2021 Jan;51(1):e13404
pubmed: 32918295
Diagnostics (Basel). 2022 Jan 06;12(1):
pubmed: 35054289
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
PLoS One. 2021 Feb 19;16(2):e0247488
pubmed: 33606842
J Infect Dis. 2021 Aug 16;224(4):565-574
pubmed: 34398242
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
J Infect Public Health. 2022 Jan;15(1):13-20
pubmed: 34861603
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
Molecules. 2020 Dec 04;25(23):
pubmed: 33291581
BMC Infect Dis. 2021 Nov 22;21(1):1173
pubmed: 34809594
Eur Heart J Qual Care Clin Outcomes. 2021 Mar 15;7(2):172-180
pubmed: 33107909
Clin Chim Acta. 2020 Aug;507:174-180
pubmed: 32339487
Sci Rep. 2021 Jan 19;11(1):1830
pubmed: 33469072
Int J Obes (Lond). 2020 Aug;44(8):1790-1792
pubmed: 32409680
Biomark Med. 2020 Sep;14(13):1207-1215
pubmed: 32692248
PLoS One. 2021 May 6;16(5):e0250956
pubmed: 33956870
Int J Infect Dis. 2020 Jul;96:467-474
pubmed: 32425643
Nature. 2021 Dec;600(7889):408-418
pubmed: 34880490
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
mBio. 2021 Feb 9;12(1):
pubmed: 33563817
F1000Res. 2020 Sep 9;9:1107
pubmed: 33163160
BMC Public Health. 2021 Aug 11;21(1):1533
pubmed: 34380456
Sci Rep. 2021 Oct 12;11(1):20254
pubmed: 34642411
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
Clin Imaging. 2020 Oct;66:35-41
pubmed: 32425338
Sci Rep. 2021 Mar 30;11(1):7166
pubmed: 33785852
Sci Rep. 2021 Jan 15;11(1):1580
pubmed: 33452298
Cell Mol Immunol. 2016 Jan;13(1):3-10
pubmed: 26189369
Aging (Albany NY). 2020 Aug 14;12(15):15670-15681
pubmed: 32805722
BMC Pulm Med. 2021 Jan 22;21(1):37
pubmed: 33482780
Int Immunopharmacol. 2020 Dec;89(Pt A):107065
pubmed: 33045571
JAMA. 2021 Apr 13;325(14):1469-1470
pubmed: 33595630
PLoS One. 2021 Feb 4;16(2):e0246295
pubmed: 33539383
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382
Sci Rep. 2021 Apr 14;11(1):8192
pubmed: 33854118
Infect Genet Evol. 2020 Apr;79:104211
pubmed: 32007627
Sci Rep. 2021 May 19;11(1):10599
pubmed: 34012016
Sci Rep. 2021 Nov 8;11(1):21807
pubmed: 34750412
BMC Infect Dis. 2021 Sep 14;21(1):951
pubmed: 34521370
EBioMedicine. 2021 Oct;72:103629
pubmed: 34655949

Auteurs

Relu Cocoş (R)

Institute of Pneumophtisiology "Marius Nasta", 050159 Bucharest, Romania.
Department of Medical Genetics, University of Medicine and Pharmacy "Carol Davila", 020032 Bucharest, Romania.

Beatrice Mahler (B)

Institute of Pneumophtisiology "Marius Nasta", 050159 Bucharest, Romania.
Pneumology Department (II), University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.

Adina Turcu-Stiolica (A)

Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Alexandru Stoichiță (A)

Institute of Pneumophtisiology "Marius Nasta", 050159 Bucharest, Romania.
Department of Cardiology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.

Andreea Ghinet (A)

Institute of Pneumophtisiology "Marius Nasta", 050159 Bucharest, Romania.

Elena-Silvia Shelby (ES)

Scientific Research Nucleus, Dr. Nicolae Robanescu National Clinical Centre for Children's Neurorecovery, 041408 Bucharest, Romania.

Laurențiu Camil Bohîlțea (LC)

Department of Medical Genetics, University of Medicine and Pharmacy "Carol Davila", 020032 Bucharest, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH